Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society ...

Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo improved response rates and duration in BRAF V600E-mutant metastatic ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed. ...